Core Viewpoint - The company has announced the achievement of the vesting conditions for the second vesting period of its 2023 restricted stock incentive plan, allowing for the allocation of 1,247,200 shares to eligible participants, representing 1.04% of the total share capital [1][10][14]. Summary by Sections 1. Overview of the 2023 Restricted Stock Incentive Plan - The plan involves the issuance of restricted stock to certain employees, excluding independent directors and supervisors, with a total of 1,247,200 shares allocated for the second vesting period [1][2]. - The plan's effective period is up to 48 months from the grant date, with specific vesting arrangements outlined for three periods: 30% for the first period, 40% for the second, and 30% for the third [2][3]. 2. Vesting Conditions and Performance Targets - The vesting conditions require a minimum revenue growth of 20% for 2023, 30% for 2024, and 40% for 2025, based on 2022 performance [4][13]. - Personal performance assessments will determine the actual number of shares vested, with ratings ranging from excellent to unsatisfactory affecting the vesting percentage [6][13]. 3. Approval and Compliance - The plan has undergone necessary approvals from the board and supervisory committee, confirming compliance with relevant regulations and internal policies [10][15]. - A legal opinion has been provided affirming that the plan's implementation adheres to applicable laws and regulations [16]. 4. Financial Impact - The allocation of 1,247,200 shares will increase the company's total share capital from 120,202,400 shares to 121,449,600 shares, which may dilute earnings per share and net asset return but is not expected to significantly impact the company's financial status [17][18]. 5. Documentation and Records - Key documents related to the board and supervisory committee meetings, as well as legal opinions, are available for review [18].
华绿生物: 关于2023年限制性股票激励计划首次授予部分第二个归属期归属条件成就的公告